Dr. Sheetal Shroff, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 285
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license Q1908 (first issued 2014; active) -
Neuromusculoskeletal Medicine & OMM Physician
TX license Q1908 (first issued 2014; active) -
Student in an Organized Health Care Education/Training Program
TX license BP1-0037509
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Houston Methodist Hospital Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Houston Methodist the Woodlands Hospital The Woodlands, TX
- Houston Methodist Clear Lake Hospital Nassau Bay, TX
- Houston Methodist Baytown Hospital Baytown, TX
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- Tmh Physician Associates PLLC (1,690 clinicians)
- Houston Methodist Specialty Physicians (1,528 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 285
- Services billed
- 762
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 193 | 151 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 186 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 120 | 57 |
| Nerve conduction, 13 or more studies | 55 | 55 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 49 | 49 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 15 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Houston, TX | 92 |
| Duloxetine Hcl Other prescribers in Houston, TX | 74 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 63 |
| Pyridostigmine Bromide Other prescribers in Houston, TX | 58 |
| Mycophenolate Mofetil Other prescribers in Houston, TX | 51 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 45 |
| Radicava Ors (edaravone) | 41 |
| Firdapse (amifampridine phosphate) | 37 |
| Azathioprine Other prescribers in Houston, TX | 36 |
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 71 payments worth $40,487 in total to this clinician.
| UCB, Inc. | $14,427 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $13,720 |
| Argenx US, Inc. | $11,803 |
| Tanabe Pharma America, Inc. | $128 |
| Alexion Pharmaceuticals, Inc. | $96.40 |
| Hospira, Inc. | $66.23 |
| Biogen, Inc. | $45.30 |
| Janssen Biotech, Inc. | $44.97 |
| Compensation for services other than consulting (speaking, faculty) | $28,250 |
|---|---|
| Consulting Fee | $9,513 |
| Food and Beverage | $1,590 |
| Travel and Lodging | $1,135 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Jan 10, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $4,500 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| UCB, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Nov 20, 2025 | Consulting Fee Rystiggo · Neurology | $2,080 |
| Argenx US, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| Argenx US, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| AstraZeneca Pharmaceuticals LP Mar 12, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
All 31 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| UCB, Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Dec 4, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Houston, TX | $10.00 |
| UCB, Inc. Dec 4, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Houston, TX | $8.54 |
| UCB, Inc. Nov 20, 2025 | Consulting Fee Rystiggo · Neurology | $2,080 |
| Argenx US, Inc. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $2,000 |
| UCB, Inc. Nov 20, 2025 | Travel and Lodging Rystiggo · Neurology · travel to San Francisco, CA | $42.00 |
| Argenx US, Inc. Nov 20, 2025 | Travel and Lodging VYVGART · Immunology · travel to Houston, TX | $18.50 |
| UCB, Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Nov 6, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Friendswood, TX | $42.00 |
| UCB, Inc. Nov 6, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Friendswood, TX | $10.00 |
| AstraZeneca Pharmaceuticals LP Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $1,050 |
| AstraZeneca Pharmaceuticals LP Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $1,050 |
| AstraZeneca Pharmaceuticals LP Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $4,300 |
| UCB, Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Oct 17, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Houston, TX | $10.50 |
| UCB, Inc. Oct 17, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Houston, TX | $10.00 |
| UCB, Inc. Oct 15, 2025 | Consulting Fee Rystiggo · Neurology | $520 |
| AstraZeneca Pharmaceuticals LP Oct 14, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Los Angeles, CA · in-kind Company’s descriptionSpeaker Expenses | $597 |
| AstraZeneca Pharmaceuticals LP Oct 14, 2025 | Travel and Lodging WAINUA · Cardiovascular and Metabolism · travel to Los Angeles, CA · in-kind Company’s descriptionSpeaker Expenses | $223 |
| Argenx US, Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $1,000 |
| Argenx US, Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $500 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| Argenx US, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,250 |
| UCB, Inc. Apr 10, 2025 | Consulting Fee Rystiggo · Neurology | $780 |
| AstraZeneca Pharmaceuticals LP Mar 12, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| AstraZeneca Pharmaceuticals LP Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) WAINUA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $1,600 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Consulting Fee WAINUA · Cardiovascular and Metabolism | $1,611 |
| Argenx US, Inc. Jan 10, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART HYTRULO · Neurology | $4,500 |
| Argenx US, Inc. Jan 10, 2025 | Travel and Lodging VYVGART HYTRULO · Neurology · travel to Shreveport, LA | $163 |
| UCB, Inc. Jan 9, 2025 | Consulting Fee Rystiggo · Neurology | $1,300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $11,923 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
UCB SA · Completed · NCT04650854 - ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.